Herisau, Switzerland – Qlupod AG, March 25, 2026 (www.qlupod.com)
Qlupod AG announces that its products will be officially listed and distributed through Galexis AG, Switzerland’s leading healthcare logistics platform, starting April 1, 2026.
With this step, Qlupod gains access to one of the most important distribution channels in the Swiss healthcare market. Through Galexis’ distribution centers in Niederbipp and Lausanne-Ecublens, more than 8,000 customers nationwide are supplied, including pharmacies, drugstores, medical practices, hospitals, and care institutions.
The inclusion in the Galexis product portfolio represents a significant milestone for Qlupod and enables the company to make its telemedicine healthcare platform accessible to an even broader medical professional audience.
Through this listing, Qlupod will in the future not only be present in the electronics and retail sectors but will also be directly available within the professional healthcare market in Switzerland.
Strategic Milestone for Nationwide Market Coverage
With its integration into the Galexis distribution structure, Qlupod achieves near-complete market coverage within the Swiss healthcare ecosystem. Qlupod’s platform solution, consisting of the Qlupod device as well as the applications QluApp, QluDoc, and QluCare, enables the digital collection and transmission of important health data, supporting both patients and medical professionals.
The QluPod was deliberately designed as a medical all round device. It combines several essential health measurements, including blood pressure, pulse, blood oxygen (SpO2), body temperature, and ECG, into a single system and can therefore replace up to five separate devices that are commonly used individually in households. This creates significantly broader usage possibilities for both patients and physicians in the areas of prevention, monitoring, and telemedical care.
Particularly in private households, this form of health monitoring is becoming increasingly important. Qlupod AG therefore pursues the vision that the QluPod will become as common in households as a blood pressure monitor or thermometer, but with significantly broader functionality.
In Switzerland, the QluPod may also be financially supported under certain conditions. For example, Swica offers the possibility of partial reimbursement if the device is prescribed by a physician. This particularly facilitates access to a comprehensive device and modern telemedical monitoring for patients with chronic conditions.
Voices on the Partnership
Nikola Trajanov, Interim CEO of Qlupod AG, states:
“The inclusion of our products in the Galexis portfolio is a decisive step for us. For decades, Galexis has been a key partner within the Swiss healthcare system. Through this listing, we can reach virtually the entire professional healthcare market in Switzerland—from pharmacies and medical practices to hospitals. At the same time, with QluPod we are bringing a device to market that combines multiple medical measurement systems in a single product, creating new opportunities for prevention, telemedicine, and patient monitoring.”
Sandra Culjaga, Head of Distribution Switzerland at Qlupod, adds:
“The collaboration with Galexis enables us to efficiently integrate Qlupod into the existing supply structure of the Swiss healthcare market. For pharmacies, physicians, and other medical institutions, it will become significantly easier to obtain our solution and incorporate it into their care concepts. At the same time, patients also benefit, as access to modern telemedical monitoring becomes considerably easier.”
Telemedicine Innovation for the Healthcare Market
The Qlupod combines multiple vital measurements within a single device and connects them with a digital platform that structures health data and makes it available to medical professionals. The goal is to efficiently connect prevention, monitoring, and telemedical care.
With its inclusion in the Galexis network, Qlupod further expands its presence in the healthcare sector and strengthens its position as a provider of integrated digital healthcare solutions.
About Qlupod:
Qlupod AG is a start-up company in the field of telemedicine and develops innovative solutions to make patient care efficient and cost effective. With the QluPod device and the associated software, the company is endeavouring to shape the future of healthcare. The offering is aimed at hospitals, care facilities, medical professionals and private individuals who want to monitor their health independently.
For more information about Qlupod AG and our products, please visit our website at www.qlupod.com.
Disclaimer:
This publication constitutes neither an offer to sell nor a solicitation to buy securities. Insofar as this document contains forward-looking statements, these do not represent facts and are characterised by the words “expect”, “believe”, “estimate”, “intend”, “aim”, “assume” and similar expressions. These statements express the intentions, opinions or current expectations and assumptions of Qlupod AG and are based on current plans, estimates and forecasts which Qlupod AG has made to the best of its knowledge, but do not claim to be correct in the future. Forward-looking statements are subject to risks and uncertainties that are difficult to predict and are generally beyond the control of Qlupod AG. It should be noted that actual events or developments may differ materially from the events and developments expressed or implied by such forward-looking statements.
Contact:
QLUPOD AG
Bahnhofstrasse 23
9100 Herisau AR – Schweiz
Tel.: +41 (0)71 510 05 45
Mail: ir@qlupod.com
Posted on March 25, 2026 by QluPod AG
Herisau, Switzerland QluPod AG (www.qlupod.com)
English 
German 
French 
Italian 
Spanish 
Albanian 
Serbian 
Macedonian 
Greek